Detecting Signals in Pharmacogenomic Genome-Wide Association Studies
In one common pharmacogenomic scenario, outcome measures are compared for treated and untreated subjects across genotype defined subgroups. The key question is whether treatment benefit (or harm) is particularly strong in certain subgroups, and therefore statistical analysis focuses on the interacti...
Main Authors: | Wakefield, Jon, Skrivankova, Veronika, Hsu, Fang-Chi, Sale, Michele, Heagerty, Patrick |
---|---|
Format: | Online |
Language: | English |
Published: |
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085158/ |
Similar Items
-
Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics
by: van Manen, Daniëlle, et al.
Published: (2012) -
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
by: Wang, Chun-Hsiang, et al.
Published: (2010) -
FDA eyes pharmacogenomics data.
by: Wakefield, Julie
Published: (2004) -
Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
by: Adkins, D E, et al.
Published: (2012) -
Whole genome sequencing in pharmacogenomics
by: Katsila, Theodora, et al.
Published: (2015)